Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
1. A bispecific antigen-binding molecule comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding domain that specifically binds human PSMA, wherein the first antigen-binding domain comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (D1-HCDR1, D1-HCDR2 and D1-HCDR3) comprising the amino acid sequences of SEQ ID NOs: 12, 14 and 16, respectively, and a light chain variable region (LCVR) comprising three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NOs: 20, 22 and 24, respectively, and the second antigen-binding domain comprises a HCVR comprising three heavy chain complementarity determining regions (D2-HCDR1, D2-HCDR2 and D2-HCDR3) comprising the amino acid sequences of SEQ ID NOs: 4, 6 and 8, respectively, and a LCVR comprising three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NOs: 20, 22 and 24, respectively.
2. The bispecific antigen-binding molecule of claim 1 , wherein the antigen-binding molecule:
(a) binds to CD28-expressing human T-cells with an EC 50 value of from 1×10 −12 M to 1×10 −6 M;
(b) binds to CD28-expressing human T-cells with an EC 50 value of from 1×10 −9 M to 1×10 −6 M;
(c) binds human cells expressing human CD28 and cynomolgus monkey cells expressing cynomolgus CD28;
(d) induces proliferation of human and cynomolgus peripheral blood mononuclear cells (PBMCs) in vitro;
(e) induces cytokine release and CD25 up-regulation in human whole blood; or
(f) induces T-cell mediated cytotoxicity of human prostatic cells.
3. A pharmaceutical composition comprising the bispecific antigen-binding molecule of claim 1 , and a pharmaceutically acceptable carrier or diluent.
4. A bispecific antigen-binding molecule comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding domain that specifically binds human PSMA,
wherein the first antigen-binding domain comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 10, and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 18; and
wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and a LCVR comprising the amino acid sequence of SEQ ID NO: 18.
5. A pharmaceutical composition comprising the bispecific antigen-binding molecule of claim 4 , and a pharmaceutically acceptable carrier or diluent.
6. An anti-CD28×anti-PSMA bispecific antibody comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 81 paired with a light chain comprising the amino acid sequence of SEQ ID NO: 83, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 82 paired with a light chain comprising the amino acid sequence of SEQ ID NO: 83.
7. A pharmaceutical composition comprising the bispecific antibody of claim 6 , and a pharmaceutically acceptable carrier or diluent.
8. A bispecific antibody that specifically binds human CD28 and human PSMA, comprising:
a first heavy chain and a light chain interconnected by disulfide bonds, wherein the first heavy chain comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (D1-HCDR1, D1-HCDR2 and D1-HCDR3) and a heavy chain constant region comprising CH1, CH2, and CH3 domains, and the light chain comprises a light chain variable region (LCVR) comprising three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) and a light chain constant region; and
a second heavy chain and a light chain interconnected by disulfide bonds, wherein the second heavy chain comprises a HCVR comprising three heavy chain complementarity determining regions (D2-HCDR1, D2-HCDR2 and D2-HCDR3) and a heavy chain constant region comprising CH1, CH2, and CH3 domains, and the light chain comprises a LCVR comprising three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) and a light chain constant region;
wherein D1-HCDR1 comprises the amino acid sequence of SEQ ID NO: 12, D1-HCDR2 comprises the amino acid sequence of SEQ ID NO: 14, D1-HCDR3 comprises the amino acid sequence of SEQ ID NO: 16, D2-HCDR1 comprises the amino acid sequence of SEQ ID NO: 4, D2-HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, D2-HCDR3 comprises the amino acid sequence of SEQ ID NO: 8, LCDR1 comprises the amino acid sequence of SEQ ID NO: 20, LCDR2 comprises the amino acid sequence of SEQ ID NO: 22, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 24.
9. The bispecific antibody of claim 8 , wherein the first heavy chain comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 10, the second heavy chain comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and the light chains each comprise a LCVR comprising the amino acid sequence of SEQ ID NO: 18.
10. A pharmaceutical composition comprising the bispecific antibody of claim 9 , and a pharmaceutically acceptable carrier or diluent.
11. The bispecific antibody of claim 8 , wherein the first heavy chain or the second heavy chain, but not both, comprises a CH3 domain comprising a H435R (EU numbering) modification and a Y436F (EU numbering) modification.
12. A pharmaceutical composition comprising the bispecific antibody of claim 11 , and a pharmaceutically acceptable carrier or diluent.
13. The bispecific antibody of claim 8 , wherein the heavy chain constant region of the first heavy chain, and the heavy chain constant region of the second heavy chain are of isotype IgG1.
14. A pharmaceutical composition comprising the bispecific antibody of claim 13 , and a pharmaceutically acceptable carrier or diluent.
15. The bispecific antibody of claim 8 , wherein the heavy chain constant region of the first heavy chain, and the heavy chain constant region of the second heavy chain are of isotype IgG4.
16. A pharmaceutical composition comprising the bispecific antibody of claim 15 , and a pharmaceutically acceptable carrier or diluent.
17. A pharmaceutical composition comprising the bispecific antibody of claim 8 , and a pharmaceutically acceptable carrier or diluent.